This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Proactive: Race Oncology completes board renewal to drive next phase of growth
Race Executive Chair Dr Peter Smith speaks with Proactive about the recent board changes and the company’s clinical pipeline for its lead drug asset, bisantrene. Read the full report here.